• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Half Yearly Report

    August 9, 2013

    In order to meet its obligations under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Conduct Authority, Shire plc (“Shire” or the “Group”) (LSE: SHP, NASDAQ: SHPG) is publishing today its Half Yearly Report for the six months ended June 30, 2013.

    It should be noted that on July 25, 2013 Shire previously announced its results in respect of the same period.


    For further information please contact:

    Investor Relations
    Eric Rojas (erojas@shire.com)
    +1 781 482 0999

    Sarah Elton-Farr (seltonfarr@shire.com)
    +44 1256 894 157

    Jessica Mann (jmann@shire.com)
    +44 1256 894 280


    Notes to editors

    Shire enables people with life-altering conditions to lead better lives.

    Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

    We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

    For further information on Shire, please visit the Group’s website: www.shire.com.

    Click here for the PDF version of this press release.